SecBot SecBot
PRESS-RELEASE ·Filed Aug 6, 2026

PHVS

Pharvaris N.V.
NEUTRAL
Impact 4/10
Horizonweeks Processed3mo ago WireGlobeNewswire
Press release · FDA
Actionable Insight • Neutral

This publication supports the scientific groundwork for the CREAATE study but provides no new clinical data or regulatory milestone. The near-term catalyst remains the Phase 3 CREAATE readout and the HAE NDA outcome. Monitor for those events, this filing alone does not change the stock's trajectory.

DirectionNeutral
Confidencehigh
Horizonweeks

deucrictibant

◆ Mixed Named in this press release
Impact
Phase
Filed/PDUFA (IR capsule); Phase 3 (XR tablet)
Time to market
IR capsule could be approved by April 23, 2027 PDUFA date. XR tablet for prophylaxis would follow later, likely 2028+ if CHAPTER-3 is positive.
Next catalyst
None dated

What to watchTwo binary catalysts in the next ~9 months: CHAPTER-3 topline (Q3 2026) and the PDUFA decision on the IR capsule (April 23, 2027). The bigger swing factor near-term is CHAPTER-3, a positive readout would validate the larger prophylactic market opportunity, while a miss would severely dent the thesis given that sebetralstat (KalVista) already beat deucrictibant to market as the first oral on-demand HAE therapy.

How the stock moved after the report

NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60
Entry
$34.45
T+0 close · Aug 6, 2026 · via day close
Latest settled
−2.53%
T+60 · $33.58
Vs SPY
−1.10%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Aug 6 $34.45entry
  2. T+1 · 3mo ago +1.34%α +0.72% · $34.91
  3. T+5 · 3mo ago −1.19%α −2.40% · $34.04
  4. T+20 · 3mo ago +3.51%α +2.91% · $35.66
  5. T+60 · 18d ago −2.53%α −1.10% · $33.58
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Pharvaris announced publication of the first in-depth qualitative study in AAE-C1INH in Frontiers in Immunology, validating PRO measures and directly informing endpoint selection for the ongoing Phase 3 CREAATE study of deucrictibant. There are currently no approved therapies for this ultra-rare, serious disease. This is a scientific milestone that supports the regulatory path but does not change the stock's near-term fundamentals.

Key Facts

  • First in-depth qualitative study in AAE-C1INH published in peer-reviewed journal Frontiers in Immunology.
  • Study validates PGI-C, PGI-S, and PGA as meaningful PRO instruments for this indication.
  • Findings directly informed design and endpoint selection for the ongoing Phase 3 CREAATE study (NCT07266805) of deucrictibant.
  • No approved therapies exist for prevention or treatment of AAE-C1INH attacks, all patients currently rely on off-label therapies.
  • Pharvaris is a late-stage biopharma developing oral bradykinin B2 receptor antagonists for bradykinin-mediated angioedema.

Financial Impact

No financial data disclosed; the announcement pertains to a disease framework publication, not financial results or deal terms.

none

Risk Factors

  • CREAATE study may fail to replicate prior deucrictibant efficacy/safety in AAE-C1INH.
  • Regulatory path for AAE-C1INH remains unclear; FDA may require additional trials beyond CREAATE.
  • Deucrictibant NDA for HAE on-demand treatment has uncertain outcome and timeline.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
90% bullish (21 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3340059

Track record

51 reports on PHVS

Performance horizon

15 of 18 bullish or bearish reports moved the stock their way by T+5. Best: +23.73% at T+20 after the Sep 17, 2026 report. 17 of 19 went positive at some point.

Filters
  1. Nov 16, 2026today SC 13G Neutral 4/10 Entry $33.19 Now $32.44 −2.26% settles Nov 23
  2. Nov 13, 20263d ago SC 13G/A Bearish 5/10 Entry $33.59 Now $32.44 +3.42% settles Nov 23
  3. Nov 12, 20264d ago Press Release Bullish 7/10 Entry $33.83 Now $32.44 −4.11% settles Nov 19
  4. Nov 12, 20264d ago 6-K Neutral 4/10 No price data
  5. Nov 12, 20264d ago Press Release Neutral 5/10 Entry $33.83 Now $32.44 −4.11% settles Nov 19
  6. Sep 25, 20267w ago Insider Cluster Bearish 6/10 Entry $32.02 to $31.19 Now $32.44 −1.31% ▲ +2.59% +2.37% vs SPY
  7. Sep 24, 20267w ago Insider Cluster Bearish 7/10 Entry $32.99 to $31.01 Now $32.44 +1.67% ▲ +6.00% +5.59% vs SPY
  8. Sep 24, 20267w ago Insider Cluster Bearish 5/10 Entry $32.99 to $31.01 Now $32.44 +1.67% ▲ +6.00% +5.59% vs SPY
  9. Sep 23, 20267w ago Insider Cluster Bearish 6/10 Entry $33.07 to $31.72 Now $32.44 +1.91% ▲ +4.08% +3.41% vs SPY
  10. Sep 21, 20268w ago Insider Cluster Bearish 5/10 Entry $36.02 to $31.91 Now $32.44 +9.94% ▲ +11.41% +10.39% vs SPY
Showing 10 of 51

US Market Status

Market Closed · Opens in 6h 40m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Aug 6, 2026